{"name":"Cinclus Pharma AG","slug":"cinclus-pharma-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Linaprazan glurate - Low dose","genericName":"Linaprazan glurate - Low dose","slug":"linaprazan-glurate-low-dose","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"Linaprazan glurate - High dose","genericName":"Linaprazan glurate - High dose","slug":"linaprazan-glurate-high-dose","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"Lansoprazole - Marketed approved dose","genericName":"Lansoprazole - Marketed approved dose","slug":"lansoprazole-marketed-approved-dose","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"Losec","genericName":"Losec","slug":"losec","indication":"Other","status":"phase_3"},{"name":"Single ascending dose of X842","genericName":"Single ascending dose of X842","slug":"single-ascending-dose-of-x842","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Linaprazan glurate - Low dose","genericName":"Linaprazan glurate - Low dose","slug":"linaprazan-glurate-low-dose","phase":"phase_3","mechanism":"Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Acid-related disorders"],"catalyst":""},{"name":"Linaprazan glurate - High dose","genericName":"Linaprazan glurate - High dose","slug":"linaprazan-glurate-high-dose","phase":"phase_3","mechanism":"Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Acid-related disorders"],"catalyst":""},{"name":"Lansoprazole - Marketed approved dose","genericName":"Lansoprazole - Marketed approved dose","slug":"lansoprazole-marketed-approved-dose","phase":"phase_3","mechanism":"Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Acid-related dyspepsia"],"catalyst":""},{"name":"Losec","genericName":"Losec","slug":"losec","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Single ascending dose of X842","genericName":"Single ascending dose of X842","slug":"single-ascending-dose-of-x842","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcEN1dUR2aXRqcTdudDBzOVR0NUJ0ZHFENHBkOFU0c2h5QXpicHJiQld3U1lwQ1U0VjFGblExVEpzS01tSDdIZ3MzOThRbzJPaDlpd0FyS3dLV3d6S1M1S0NRY1pfSld0a2JJakhDOWsyem1lSG9nNHU3cGhfczZDS3hpVFhnWkZmemI3dy0ydmVPZG1hdHBEX0VTQnYtUml6LW94dlhOcVJjM3hRNXh2ekc3REhUYnowZ2twSElSOG83VU5VQUtiY3VSMEFZOGdQWVhCV2REYWFSU1AxQng1YkJIN0FCYWFIVUpWRmxtMVZNR0NuMjRvOQ?oc=5","date":"2026-03-13","type":"deal","source":"lincolnjournal.com","summary":"Claret Capital Partners invests €28M in Cinclus Pharma - lincolnjournal.com","headline":"Claret Capital Partners invests €28M in Cinclus Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNTW5PRHRPckU4NnlPRkZNVTNkZ3pXa2pkeFVTUFk1VG1WY19ZVFNtd2dVblJHM2UtZWpQZUswT2NwMjhQRUNpejRsQzBLZ2VveGQ4UTYzSnJ2bG9NYmpkNHRDMFJTMTRxaE9QbG1sR1hlV2d3M2pzX2tSdXBVbTRiMjV2bmQ3elFucWR6SXIxeTQ5UXlxd1ppV1BNY01WTENja2tZcGFiSVg2RFBSbVA2Q3cxNXA5Z2x4STJFdHFkVkFxRlI5M0VLdGNHTFI3VzlDUXREUEZTdXNUUUk4UHJ0bFRZODhnOXU3dDQ2M256S19ZQVcwNjR0dndqQV9hZktVV2RJUGZEZ2dncERCWHh5WHhCRjF5cjFV?oc=5","date":"2026-03-04","type":"pipeline","source":"PR Newswire","summary":"H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight - PR Newswire","headline":"H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPY3dEMEIwYnZxX0duWDlGRGFiQjgwZkx4MHJtUEQwa09TaWpfVF9oTTI3cGtxUWJNWTBOU1k4Mkg5aVhacDlKeER2dGxxY0owRlk5cm1peEp6NmlBUDlWcTlySnRBWENzcl9tQTNfZU0xVWhoUGJrMWg0WmRTNl9EUVdDaHd4YVp4Yjdla1JQUGxTbkplWjR4dHhZZmRfaEZxcGk4WjFmMjNNdElHMjZQU2NjSUJiSFNHS0lFUWpXRkNHcVBDWnFIWnctcVlpd2Q1VVdwbl94YzZSY0t6TkpNS1ZCRHBHaGRfMDQ4N0RHQWNULXZGdmc?oc=5","date":"2025-12-08","type":"pipeline","source":"Finansavisen","summary":"Notice of Extraordinary General Meeting in Cinclus Pharma Holding AB (publ) - Finansavisen","headline":"Notice of Extraordinary General Meeting in Cinclus Pharma Holding AB (publ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOOWNSc3Axcm5oX3pyTktjS2I1cGEwSU9kY3VSX3dsZDBWSXZ0OHVaX3MwdklqUzFaYi1HdEFWNkRBRGFtbmxjMl9RVEtIeUo2NjBYQjljb2lQNnZyMFJtanp1a2RGQ1lRSENBLUVYYWdMVUMxTlotRldvb2h2VDZEZ0JhZmRtcmpaVFI4WDI1QkV0MFphcXcwTlN4azVvTTJ2NGEwb2NteFhVUkd6N1RZYS13cmZqQQ?oc=5","date":"2025-05-22","type":"deal","source":"Fierce Pharma","summary":"Zentiva inks €220M deal to commercialize AstraZeneca GI cast-off in Europe - Fierce Pharma","headline":"Zentiva inks €220M deal to commercialize AstraZeneca GI cast-off in Europe","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":4,"phase_1":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}